Ascendis Pharma

Rank#1475

Market Cap14.84B

CountryDenmark

Summary

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

History

Ascendis Pharma was founded in 2005 in Copenhagen, Denmark with the mission of revolutionizing treatments for rare and complex diseases. The company built a robust platform with state-of-the-art drug development technologies to provide new treatments for diseases with few or no available treatments.

Mission

Ascendis Pharma creates technologies to transform medicine and enable treatments to reach those with rare and complex diseases across the globe.

Vision

Ascendis Pharma will be recognized as the leader in the development of transformative treatments for rare and complex diseases that provide superior therapeutic benefit with improved convenience and compliance.

References

https://in.investing.com/equities/ascendis-pharma-as

https://finance.yahoo.com/quote/ASND/profile?p=ASND

https://www.comparably.com/companies/ascendis-pharma-a-s/mission

https://www.crunchbase.com/organization/ascendis-pharma

https://sec.report/CIK/0001612042

https://companiesmarketcap.com/

https://ascendispharma.com

Leadership team

Mr. Jan Moller Mikkelsen (Pres, CEO, Member of Exec. Board & Exec. Director)

Mr. Michael Wolff Jensen L.L.M. (Sr. VP, Chief Legal Officer & Member of the Exec. Board)

Dr. Birgitte Volck M.D., Ph.D. (Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs)